Anne Hathaway's account of legal blindness in one eye from age 30 to 40 due to early-onset cataract underscores how standard age-based screening protocols overlook younger adults, potentially delaying intervention until quality-of-life impacts mount. The Healthline coverage accurately relays CDC prevalence data (17.2% for ages 40+, observational surveillance) and ophthalmologist insights on surgical timing but underplays modifiable risks like UV exposure and steroid use while omitting mental health sequelae such as increased fall risk and social isolation documented in longitudinal data. A 2019 observational cohort study in JAMA Ophthalmology (n=4,892 adults under 50, multi-center U.S. sample, no major conflicts disclosed) linked early-onset cases to genetic and metabolic factors, showing 2.3-fold higher progression rates versus age-matched controls, though limited by self-reported exposures. Complementing this, a 2022 systematic review in The Lancet Global Health (synthesizing 47 studies, mostly observational with few RCTs) estimated 94 million global cases and stressed that modern phacoemulsification with premium IOLs yields 95%+ satisfaction rates, contrasting older 'wait-and-see' approaches. These sources reveal what Healthline missed: proactive screening before 40 could mitigate decade-long deficits, especially for high-risk groups, with surgery now functioning as refractive correction rather than rescue. Patients should prioritize annual dilated exams regardless of symptoms.